PharmaPoint: Alzheimer's Disease - China Drug Forecast and Market Analysis to 2022

NEW YORK, Oct. 2, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Alzheimer's Disease - China Drug Forecast and Market Analysis to 2022

http://www.reportlinker.com/p01658537/PharmaPoint-Alzheimer's-Disease---China-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

PharmaPoint: Alzheimer's Disease - China Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, "PharmaPoint: Alzheimer's Disease - China Drug Forecast and Market Analysis to 2022". There are no long-term effective therapies for Alzheimer's Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.

Being the most populated nation in the world and having a government with ample resources, China could potentially observe astounding AD drug growth during the forecast period. Unfortunately, we do not envision this to occur within the next 10 years due to China's acceptance of its underdeveloped healthcare infrastructure. The lack of access to healthcare in rural parts of the nation, the limited provision of social services, and limited efforts to maintain adequate public health suggest that there are many areas that require significant changes before the topic of AD can be properly addressed.

Scope - Overview of Alzheimer's Disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in China from 2012-2022.

- Analysis of the impact of key events as well the drivers and restraints affecting China Alzheimer's Disease market.

Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for Alzheimer's Disease

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of drug performance

- Obtain sales forecast for drugs from 2012-2022 in China

Table of Contents

1 Table of Contents 51.1 List of Tables 81.2 List of Figures 92 Introduction 102.1 Catalyst 102.2 Related Reports 113 Disease Overview 133.1 Etiology and Pathophysiology 143.1.1 Etiology 143.1.2 Pathophysiology 173.2 Symptoms 294 Disease Management 314.1 Diagnosis 314.1.1 Probable Alzheimer's Disease Dementia 324.1.2 Possible AD Dementia 334.1.3 Probable AD Dementia with Evidence of AD Pathophysiological Process 334.1.4 Possible Alzheimer's Dementia with Evidence of the Alzheimer's Disease Pathophysiological Process 344.1.5 Preclinical AD 344.1.6 Mild Cognitive Impairment 354.2 Treatment Overview 374.3 China 404.3.1 Diagnosis 404.3.2 Clinical Practice 405 Competitive Assessment 425.1 Overview 425.2 Strategic Competitor Assessment 425.3 Product Profiles - Major Brands 455.3.1 Aricept (donepezil hydrochloride) 455.3.2 Exelon (rivastigmine, rivastigmine tartrate) 495.3.3 Razadyne (galantamine hydrobromide) 545.3.4 Namenda (memantine hydrochloride) 586 Opportunity and Unmet Need 626.1 Unmet Needs Overview 626.1.1 Public Awareness 646.1.2 Specialized Institutions at Local Levels 656.1.3 Screening and Diagnosis 656.1.4 Early Intervention 666.1.5 Improved Clinical Trial Design 676.1.6 Effective Therapy 686.1.7 Behavioral Treatments 696.2 Gap Analysis 696.2.1 Disease Prevention 706.2.2 Diagnosis from Biomarkers 716.2.3 Behavioral Therapies 727 Pipeline Assessment 737.1 Overview 737.2 Early-Stage Pipeline Assessment 737.3 AD Pipeline by Mechanism of Action 757.4 Enzymatic Processing 767.5 Immunization 777.6 Anti-Aggregation 777.7 "Me-Too" 787.8 Novel Therapeutic Approaches 797.9 Technology Trends Analytic Framework 797.10 Promising Drugs in Clinical Development 808 Market Outlook 828.1 China 828.1.1 Forecast 828.1.2 Key Events 858.1.3 Drivers and Barriers 859 Appendix 879.1 Bibliography 879.2 Abbreviations 989.3 Methodology 1049.4 Forecasting Methodology 1049.4.1 Diagnosed AD patients 1049.4.2 Percent Drug-treated Patients 1059.4.3 Drugs Included in Each Therapeutic Class 1059.4.4 General Pricing Assumptions 1069.4.5 Individual Drug Assumptions 1069.4.6 Generic Erosion 1089.5 Physicians and Specialists Included in this Study 1089.6 About the Authors 1099.6.1 Author 1099.6.2 Global Head of Healthcare 1109.7 About GlobalData 1119.8 Disclaimer 111

List of Tables Table 1:Symptoms of AD 30

Table 2:Guidelines for the Treatment of AD 37

Table 3:Most Prescribed Drugs for AD by Class in the Global Markets, 2012 38

Table 4:Leading Branded Treatments for AD, 2013 43

Table 5:Product Profile - Aricept 46

Table 6:Aricept SWOT Analysis, 2013 49

Table 7:Product Profile- Exelon 50

Table 8:Exelon SWOT Analysis, 2012 53

Table 9:Product Profile - Razadyne 55

Table 10:Razadyne SWOT Analysis, 2013 57

Table 11:Product Profile- Namenda 59

Table 12:Namenda SWOT Analysis, 2013 61

Table 13:Overall Unmet Needs - Current Level of Attainment 63

Table 14:Clinical Unmet Needs - Gap Analysis, 2013 70

Table 15:Technology Trends Analytic Framework for the AD Pipeline, 2012 80

Table 16:Comparison of Therapeutic Classes in Development for AD, 2013 80

Table 17:Comparison of Therapeutic Classes in Development for AD, 2013 81

Table 18:Sales Forecasts ($m) for AD in China, 2012-2022 83

Table 19:Key Events Impacting Sales for AD in China, 2012-2022 85

Table 20:AD Market in China - Drivers and Barriers in China, 2012-2022 85

List of Figures Figure 1:Atrophy of the Brain in AD 19

Figure 2:Key Pathological Features in AD Versus a Healthy Neuron 21

Figure 3:Non-Amyloidogenic Metabolism of APP 23

Figure 4:Amyloidogenic Metabolism of APP 24

Figure 5:Neurofibrillary Tangles 26

Figure 6:Oxidative Damage Due to Free Radicals 28

Figure 7:Strategic Competitor Assessment of the Marketed Products in AD, 2013 44

Figure 8:AD - Pipeline Drugs by Target, 2012 74

Figure 9:Competitive Assessment of Late-Stage Pipeline Agents in AD, 2012-2022 81

Figure 10:Sales for AD in China by Drug Class, 2012-2022 84

To order this report: PharmaPoint: Alzheimer's Disease - China Drug Forecast and Market Analysis to 2022http://www.reportlinker.com/p01658537/PharmaPoint-Alzheimer's-Disease---China-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

 

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.